🇺🇸 CCNU in United States

110 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Platelet Count Decreased — 16 reports (14.55%)
  2. Off Label Use — 15 reports (13.64%)
  3. Fatigue — 12 reports (10.91%)
  4. Product Use In Unapproved Indication — 11 reports (10%)
  5. Neuropathy Peripheral — 10 reports (9.09%)
  6. Second Primary Malignancy — 10 reports (9.09%)
  7. Weight Decreased — 10 reports (9.09%)
  8. Malignant Neoplasm Progression — 9 reports (8.18%)
  9. Mucosal Inflammation — 9 reports (8.18%)
  10. Acute Hepatic Failure — 8 reports (7.27%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is CCNU approved in United States?

CCNU does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for CCNU in United States?

Radiation Therapy Oncology Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.